Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed · Phase 3

Conditions studied: Moderate to Severe Chronic Plaque Psoriasis

In brief

This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.

Key facts

Study ID

NCT04785326

Run by

Dong-A ST Co., Ltd.

People needed

598

Starts

2021-04-28

Expected to finish

2022-11-16

Last updated by the study team

2024-01-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have a diagnosis of plaque-type psoriasis for at least 6 months.

You may not qualify if…

• Patients with hypersensitivity to ustekinumab or any of the product excipients.

Where it is running

• Central Sooner Research — Norman, Oklahoma, United States
• Jordan Valley Dermatology Center — West Jordan, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.